| Not Yet Recruiting | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors NCT07088588 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Recruiting | MEASUREMENT OF CIRCULATING MUTATION BURDEN NCT06792721 | Centre Francois Baclesse | — |
| Not Yet Recruiting | Robotic Nipple Sparing Mastectomy with Immediate Reconstruction NCT06860217 | European Institute of Oncology | N/A |
| Recruiting | MiniLap Vs Standard Laparoscopy in Prophylactic Bilateral Salpingo-oophorectomy in BRCA-Mutated Patients NCT06831747 | Azienda Sanitaria-Universitaria Integrata di Udine | N/A |
| Recruiting | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Not Yet Recruiting | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss NCT06614751 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Active Not Recruiting | A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY NCT06497270 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766 | Okayama University | Phase 2 |
| Active Not Recruiting | Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer NCT06436248 | Abramson Cancer Center at Penn Medicine | — |
| Enrolling By Invitation | Prophylactic Prostatectomy for Prostate Cancer (PPPC) NCT06470685 | Royal Marsden NHS Foundation Trust | — |
| Active Not Recruiting | Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion NCT06033092 | European Institute of Oncology | Phase 2 |
| Not Yet Recruiting | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinoma NCT06393543 | Radboud University Medical Center | — |
| Recruiting | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519 | 858 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation NCT06405295 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors NCT06177171 | Pamela Munster | Phase 1 |
| Completed | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations NCT05904730 | Lynkcell Europe | Phase 1 |
| Recruiting | Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer NCT06783127 | Santa Chiara Hospital | — |
| Completed | Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Posit NCT05771454 | Aga Khan University Hospital, Pakistan | — |
| Active Not Recruiting | The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics NCT05692596 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Unknown | Quality of Sexual Function in BRCA Mutated Women NCT05456919 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Withdrawn | Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage NCT05554211 | Northwestern University | Phase 2 |
| Unknown | A Training Set for the HRD Model in EOC NCT04651933 | Lei Li | — |
| Unknown | Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors NCT03415659 | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | Phase 1 |
| Unknown | A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previousl NCT02639832 | Cynvenio Biosystems | — |
| Recruiting | The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. NCT05097274 | Institute of Cancer Research, United Kingdom | — |
| Active Not Recruiting | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Ba NCT01844986 | AstraZeneca | Phase 3 |
| Unknown | Patient Empowerment by Group Medical Consultations NCT01329068 | Radboud University Medical Center | N/A |
| Active Not Recruiting | The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer NCT00261456 | Institute of Cancer Research, United Kingdom | — |